Bovine Pancreas
1. Identity
1.1 Source and Nomenclature
Bovine pancreas refers to the whole pancreatic gland, or concentrated extracts derived from it, obtained from domestic cattle (Bos taurus). As a dietary supplement, it is marketed in both whole-gland and extract form. As an organ, the pancreas produces essential digestive enzymes (such as lipase, protease, and amylase) and regulates blood sugar through the production of insulin and glucagon.
The pancreas is a relatively large gland located near the small intestine and stomach that spans a large part of the upper abdomen over to the spleen. When used in supplements, it is classified as a "glandular" product. Glandular therapy refers to the use of animal tissues to try to enhance the function of, or mimic the effect of, the corresponding human tissue.
The primary concentrated preparation derived from the bovine (and porcine) pancreas is known as pancreatin. Pancreatin is a mixture of several digestive enzymes produced by the exocrine cells of the pancreas; it is composed of amylase, lipase, and protease. A related standardized pharmaceutical preparation is pancrelipase. Pancrelipase is a combination of lipase, protease, and amylase enzymes used to treat exocrine pancreatic insufficiency due to cystic fibrosis and other gastrointestinal disorders.
1.2 Animal Sources
An effective way to supplement missing digestive enzymes in people with insufficient pancreatic function is to ingest an extract created from an animal pancreas. The most common sources are bovine (cow), porcine (pig), and ovine (sheep). The enzymes used in such medicaments derive from bovine or swine pancreas. Most glandular products are from a bovine source, since it is easier to collect tissue from larger animals.
1.3 Common Forms and Preparations
Bovine pancreas is available in several distinct forms:
- Whole desiccated (freeze-dried) glandular: Grass-fed beef pancreas is available as a whole food dietary supplement that provides 100% pure bovine pancreas. Freeze-dried varieties have been noted to optimally preserve nutritional factors and co-factors.
- Pancreatin powder/tablets/capsules: Pancreatic extract can be found in products from several different sources, such as tablets or capsules. Pancreatin is a concentrated form of bovine-derived digestive enzymes standardized for protease, lipase, and amylase activity.
- Enteric-coated preparations: Pharmaceutical-grade formulations are often enteric-coated to protect enzymes from gastric acid destruction, enabling delivery to the duodenum.
2. Traditional and Historical Use
2.1 Ancient and Indigenous Practices
Animal glands have been valued as food and as medicine for millennia. Weston A. Price, in his book Nutrition and Physical Degeneration, described the dietary habits of indigenous peoples around the world that he had observed during his travels in the early twentieth century, noting that for the Eskimos of Alaska the native diet consisted of a liberal use of organs and other special tissues of the large animal life of the sea, as well as of fish.
The concept behind glandular therapy is rooted in a principle that goes back centuries: "like supports like" — the idea is that consuming tissue from a specific gland provides targeted nutritional support for that same gland in one's own body. In traditional cultures, pancreas was fed to people with digestive and endocrine problems.
In traditional and ancestral medicine, although rarely isolated, the pancreas may have been consumed along with other organs in nose-to-tail eating, contributing to overall vitality through its enzyme-rich content.
2.2 Early 20th Century: Glandular Therapy Movement
While the pancreas was not commonly consumed as a food, it gained therapeutic use in the early 20th century through glandular therapy, a practice that uses animal organs to support the healing of their human counterparts. This concept was especially advanced by practitioners of naturopathic and European biological medicine, who observed improved digestion, inflammation control, and energy in patients taking pancreatic extracts.
Glandular therapy, or organotherapy, refers to the use of specific animal tissues and cell preparations to improve physiologic functioning and to support the natural healing process. In the 1930s, when glandular use in clinical practice was commonplace, physicians such as Henry Harrower, M.D., W. Powell Cortrille, D.O., Francis Pottenger, M.D., and Royal Lee, D.D.S. emphasized the importance of supplementation with glandulars.
In the late 1800s, treatment with thyroid extract caused dramatic improvement in patients with myxedema. Shortly thereafter, multiple other glandular extracts became available, both individually and in combinations. Their use gradually fell into disfavor, partly due to overpromotion by the manufacturers.
The pancreas is one of the first glandular extracts ever studied by the scientific community, and it was this research that led to the development of the first treatments for diabetes.
2.3 Development of Pancreatin as a Therapeutic Agent
The concept of enzyme therapy was further developed with the creation of pancreatin, often used in treating digestive enzyme deficiency, chronic pancreatitis, and conditions like celiac disease or cystic fibrosis. Pancreatic enzyme supplementation has a long history of use in the medical and nutrition literature.
While the role of the pancreas in blood sugar control was recognized as early as 1893, and a few reports of successful treatment of diabetics with oral pancreas appeared in the 1920s, academics of the time dismissed those reports.
3. Key Constituents and Active Compounds
3.1 Exocrine Enzymes
The principal bioactive constituents of bovine pancreas are the exocrine digestive enzymes. Pancreatic enzymes have an important role in digestion. The pancreas is responsible for the production of lipase (breaks down fat molecules), protease (breaks down proteins), and amylase (processes carbohydrates).
- Lipase: Lipase enzymes hydrolyse fats to glycerol and fatty acids.
- Amylase: Amylase converts starch into dextrins and sugars.
- Protease (including trypsin and chymotrypsin): Protease enzymes change proteins into proteoses and derived substances.
- Trypsin and colipase: The presence of cofactors such as colipase, a pancreatic peptide, and calcium, which is needed to activate many proteolytic enzymes, enhance the effectiveness of pancreatic enzymes.
3.2 Endocrine Peptides and Other Constituents
The bovine pancreatic polypeptide (BPP) is a straight-chain sequence of thirty-six amino acid residues. Bovine pancreas contains high concentrations of peptides that occur exclusively in this organ. Bovine pancreas is also rich in essential nutrients, cofactors, and enzymes.
Beyond the catalogued enzymes, the whole glandular tissue also contains proteins expressed exclusively in pancreatic tissue. Pancreas glandular naturally provides the digestive enzymes amylase, trypsin, protease, and lipase along with proteins exclusively expressed in pancreas tissue.
3.3 Established Mechanisms of Action
Exocrine pancreatic insufficiency (EPI) is characterized as decreased synthesis or secretion of pancreatic enzymes and bicarbonate, and occurs with parenchyma dysfunction or reduction or ductal obstruction due to preexisting pancreatic diseases, leading to the maldigestion of food and subsequently malabsorption of nutrients.
Supplemental pancreatic enzymes function by directly replacing the endogenous enzymatic activity that is deficient. It is theorized that supplementing with pancreatic glandular extract can provide the body with the nutrients, cofactors, precursors and enzymes necessary to promote proper pancreatic function.
A recent review article detailed a much wider role in physiology for proteases than previously believed, because they can modulate many cellular reactions through protease-activated receptors in cell membranes. Protease-activated receptors help regulate intestinal permeability, and proteases may interact with those receptors to facilitate their own absorption. Finally, since ingested pancreas can improve the digestion of food, changes in the microbiome could have a systemic effect.
4. Scientific Evidence by Area of Use
4.1 Exocrine Pancreatic Insufficiency (EPI)
This is the indication with the strongest and most robust clinical evidence for pancreatic enzyme preparations (including those of bovine origin).
Pancreatic enzyme replacement therapy (PERT) is widely applied to patients with exocrine pancreatic insufficiency (EPI). EPI, characterized as decreased synthesis or secretion of pancreatic enzymes and bicarbonate, occurs with parenchyma dysfunction or reduction or ductal obstruction due to preexisting pancreatic diseases, leading to the maldigestion of food and subsequently malabsorption of nutrients. The common clinical symptoms remain recurrent abdominal pain, flatulence and weight loss, accompanied with typical steatorrhea in the case of pancreatic lipase output decrease to less than 10% of normal.
A 2017 meta-analysis published in Oncotarget and indexed in PubMed directly assessed the clinical evidence: The analysis searched PubMed, Medline, and the Cochrane library for prospective randomized controlled trials (RCTs). Seven RCTs randomizing a total of 282 patients were identified. PERT significantly increased the coefficient of fat absorption (CFA) compared with baseline (WMD: 26.56, P < 0.001) and vs. placebo (WMD: 17.97, P < 0.001). Meanwhile, the coefficient of nitrogen absorption, stool fat excretion, stool nitrogen excretion, and stool weight were significantly improved in PERT compared with both baseline and placebo, with no statistical differences in adverse events.
In the last two decades, a number of studies comparing pancreatic enzymes and placebo have confirmed that pancreatic enzymes are superior to placebo for treatment of pancreatic malabsorption. While many patients achieved a satisfactory clinical response, individualization is often needed. Studies conclusively show that dose escalation is not a reliable method of obtaining further improvements and instead results in increased costs.
Evidence strength: Strong. Multiple RCTs and a meta-analysis support the efficacy of PERT in EPI. This is the principal medically-established use of pancreatic enzyme preparations.
4.2 Cystic Fibrosis (CF)
Pancreatic insufficiency (PI) remains a significant issue for the majority of individuals with cystic fibrosis. The majority of individuals with CF are pancreatic insufficient. The provision of safe and effective pancreatic enzyme replacement is a key therapy in CF.
Left untreated, pancreatic insufficiency in CF could lead to growth failure, weight loss, abdominal bloating, foul-smelling stools, or diarrhea. The use of pancreatic enzyme replacement therapy (PERT) has helped to alleviate these symptoms.
A 2019 prospective interventional study in 43 paediatric CF patients from 5 European centres found that median coefficient of fat absorption was 90% (84–94%, 1st–3rd quartile). Strict adherence to the theoretical optimal dose of enzymatic supplement for a prescribed meal led to median CFA levels at the clinical target of 90% with low variability between patients.
Evidence strength: Strong for symptom management and nutritional support. PERT for CF is a well-established standard of care supported by clinical guidelines from organizations including the Cystic Fibrosis Foundation.
4.3 Chronic Pancreatitis
Chronic pancreatitis damages pancreatic exocrine tissue, progressively reducing enzyme output. The 2017 meta-analysis (described above under EPI) included RCTs in patients with chronic pancreatitis alongside those with pancreatic surgery as its primary populations. Seven RCTs randomizing 282 patients were assessed. PERT significantly improved fat absorption compared to both baseline and placebo. Subgroup analysis indicated that standard forms of PERT displayed more effectiveness with significantly decreased heterogeneity.
Evidence strength: Moderate-to-strong. The evidence base includes multiple RCTs, though total patient numbers remain relatively small and heterogeneity in study populations and formulations is a limitation.
4.4 Post-Surgical Pancreatic Insufficiency
Surgical resection of pancreatic tissue (including pancreatectomy) can result in EPI. Pancreatin mixture is used to treat conditions in which pancreatic secretions are deficient, such as surgical pancreatectomy, pancreatitis, and cystic fibrosis. Clinical trial protocols have been developed for assessing PERT specifically in the context of pancreatic cancer surgery and resection, with fat absorption as the primary endpoint.
Evidence strength: Moderate. Supported by sub-studies within the broader PERT literature, though dedicated large RCTs in post-surgical populations remain limited.
4.5 Pancreatic Cancer–Related EPI
Patients with pancreatic cancer often develop exocrine insufficiency. A Lancet-published placebo-controlled trial of enteric-coated pancreatin microsphere treatment in patients with unresectable pancreatic head cancer (Bruno et al., 1998) is among the established references in this field, specifically examining enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region (Gut, 1998, 42:92–96).
Evidence strength: Preliminary-to-moderate. There is supporting clinical trial data, but trial sizes are small and the oncological complexity of these patients makes interpretation difficult.
4.6 Diabetes and Blood Sugar Regulation
The historical interest in oral pancreas for diabetes was not pursued scientifically for decades after early 20th-century reports. Reddy et al. found that oral administration of syngeneic pancreatic extract to young diabetes-prone mice significantly decreased the development of diabetes. However, this represents animal-model evidence only, and there are no established human clinical trials specifically evaluating whole bovine pancreas glandular supplements for glycemic control in humans.
Evidence strength: Preclinical (animal data) only. No controlled human clinical trial evidence supports the use of bovine pancreas glandular supplements for diabetes management.
4.7 General Digestive Support in Otherwise Healthy Individuals
Many naturopathic practitioners believe that it is not too much acid but rather a lack of acid that is the problem in indigestion. In addressing indigestion, naturopathic doctors use measures to enhance rather than inhibit digestion. Commonly used digestive aids include betaine HCl and pancreatic enzymes.
Evidence strength: Very weak. There are no rigorous human RCTs evaluating whole-gland bovine pancreas supplements for digestive support in otherwise healthy individuals. The well-established clinical evidence applies only to populations with documented pancreatic enzyme deficiency.
5. Body Systems and Health Areas
The following are the body systems and health areas with which bovine pancreas is associated, based on its established biological roles and documented clinical applications:
- Gastrointestinal/Digestive System: The most primary association. Enzyme replacement for maldigestion, steatorrhea, bloating, and nutrient malabsorption in EPI, chronic pancreatitis, cystic fibrosis, and post-surgical states.
- Endocrine/Pancreatic System: The pancreas produces essential digestive enzymes and regulates blood sugar through the production of insulin and glucagon. The glandular theory proposes support for pancreatic tissue function, though this is not clinically established for whole-gland supplements.
- Nutritional/Metabolic: EPI leads to maldigestion of food and subsequently malabsorption of nutrients. By restoring enzyme activity, PERT supports macro- and micronutrient absorption.
- Immune/Mucosal: Protease-activated receptors help regulate intestinal permeability, and proteases may interact with those receptors.
6. Dosage Forms and Reported Dosages
The recommended amount may vary according to the potency and method of preparation of the particular product.
6.1 Pharmaceutical Preparations (Clinically Studied Dosages)
In pharmaceutical-grade PERT, dosage is expressed in lipase units (LU) and calibrated to meal fat content and body weight:
- The recommended dosing for meals in cystic fibrosis ranges from 500–2,500 lipase units/kg/meal.
- Fibrosing colonopathy has been reported following treatment with pancreatic enzyme products. The recommended maximum dosage is 2,500 lipase units/kg/meal (or 10,000 lipase units/kg/day) or 4,000 lipase units/g fat ingested/day in adult and pediatric patients greater than 12 months of age without further investigation.
- Studies showed that approximately 30,000 USP units of unprotected lipase given with meals could abolish steatorrhea in patients with varying degrees of acid secretory capacity.
- Seven patients with cystic fibrosis taking high doses of pancreatin supplements were assessed to determine whether the dose was necessary to achieve adequate fat absorption; patients reduced their intake from a group mean of 45 to 21 capsules a day.
6.2 Dietary Supplement Preparations (As Labeled)
Six capsules of typical whole-gland desiccated supplement provides the equivalent of one ounce of fresh, raw whole bovine pancreas. Dosing and potency of unregulated dietary supplement forms are not standardized, and labeled amounts are not equivalent to pharmaceutical-grade dosages.
7. Safety Considerations and Interactions
7.1 Fibrosing Colonopathy
Fibrosing colonopathy is a rare serious adverse reaction initially described in association with high-dose pancreatic enzyme use, usually with use over a prolonged period of time and most commonly reported in pediatric patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. It is uncertain whether regression of fibrosing colonopathy occurs.
In several patients with cystic fibrosis, including children, high doses of pancreatin caused fibrosing colonopathy — a narrowing of the colon and ileocecal part of the intestine. Fibrosing colonopathy and colonic strictures are associated with chronic high-dose pancreatic enzyme use over a prolonged period of time, with enzyme doses in excess of 6,000 LU/kg body weight per meal or 10,000 LU/kg/day in patients with cystic fibrosis.
7.2 Hyperuricemia and Renal Effects
Hyperuricaemia and hyperuricosuria have been reported to occur in cystic fibrosis patients; pancreatin extracts contain a small amount of purine which might, in high doses, contribute to this condition. Pancreatic enzyme products contain purines that may increase blood uric acid levels. High dosages have been associated with hyperuricosuria and hyperuricemia. Blood uric acid levels should be monitored in patients with gout, renal impairment, or hyperuricemia during treatment.
7.3 Allergic Reactions
In clinical studies with pancreatic enzymes, hypersensitivity to the pharmaceuticals was identified as a major side effect. Because glandular products are animal products, meat allergies would be expected to cause reactions. Patients with alpha-gal syndrome should certainly avoid glandular products, although one study reported that two such patients with pancreatic insufficiency were able to tolerate porcine pancreatic enzymes despite positive skin-prick testing.
7.4 Common Adverse Effects
The most common side effects associated with taking pancreatic enzyme products in clinical trials were abdominal pain, hyperglycemia, hypoglycemia, frequent abnormal bowel movements, flatulence, vomiting, dizziness, sore throat, and cough. Inappropriately large doses could result in abdominal discomfort, nausea, vomiting, and perianal irritation or inflammation.
7.5 BSE/Prion Risk and Regulatory Framework
Because bovine pancreas is derived from cattle, it is subject to regulations governing bovine spongiform encephalopathy (BSE). The FDA has issued a final rule prohibiting the use of certain cattle material to address the potential risk of bovine spongiform encephalopathy (BSE) in human food, including dietary supplements, and cosmetics. Designated prohibited cattle materials include specified risk materials (SRMs), the small intestine from all cattle (unless the distal ileum has been removed), material from nonambulatory disabled cattle, and material from cattle not inspected and passed.
The FDA is taking this action to minimize human exposure to certain cattle material that could potentially contain the BSE agent. The U.S. has long had measures in place to prevent the introduction and spread of BSE, and therefore the risk of human exposure to the BSE agent from FDA-regulated human food and cosmetics is considered negligible.
It is critically important to use good-quality materials to avoid the prions that cause bovine spongiform encephalopathy (BSE). Even before the advent of BSE, Australia and New Zealand had strict restrictions on the importation of animals and animal products for many years, and no cases of BSE have occurred in Australia or New Zealand.
7.6 Viral Transmission Risk
There is a theoretical risk of viral transmission with all pancreatic enzyme products. For porcine-derived products specifically, a 2024 study published in Gut found that patients with cystic fibrosis had disproportionate rates of hepatitis E virus (HEV) seropositivity regardless of transplant status. Chronic HEV infection was evident only in CF transplant recipients. HEV may represent a significant risk for people with CF, particularly post-transplant.
7.7 Drug Interactions
No direct pharmacokinetic drug interaction studies with bovine pancreas glandular supplements as dietary products have been identified in peer-reviewed literature. However, for pharmaceutical-grade preparations: oral mucosa irritation can result from enzyme products being chewed or retained in the mouth rather than swallowed. Caution should be exercised when prescribing pancreatic enzyme products to patients with gout, renal impairment, or hyperuricemia.
7.8 Evidence Gap: Dietary Supplement vs. Pharmaceutical Grade
The clinical evidence and safety data described above apply principally to regulated, standardized pharmaceutical PERT formulations. Whole desiccated bovine pancreas dietary supplements are not subject to the same regulatory standards, and these products have not been evaluated by the Food and Drug Administration. The enzyme activity, purity, and bioavailability of unregulated glandular supplements may differ substantially from studied pharmaceutical preparations.
References
Go back